Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Clinical trial NCT00657488 · COMPLETED

Trial details

NCT number: NCT00657488
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2001-12-01
Primary completion: 2005-10-01
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.